CSI Market
Sign In | Register

Citius Pharmaceuticals Inc (CTXR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CTXR Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Citius Pharmaceuticals Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
9 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-87.74
Depreciation & amortization0.00
Amortization of Other Assets0.18
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.34
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation11.99
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss-
Stock Issued During Period Value Issued For Services-
Stock Issued During Period Value New Issues-
Unit Purchase Option Issued For Services-
Warrants Issued And Repriced In Settlement Agreements-
Loss Gain On Revaluation Of Derivative Warrant Liability-
Issuance Of Common Stock For Services-
Amortization Of Operating Lease Rightofuse Asset-
Gains Losses On Restructuring Of Debt-
Increase Decrease In Accrued Compensation-
Issuance Of Common Stock Warrant0.07
Increase Decrease In Operating Lease Liability-0.01
Amortization And Accretion Of Operating Lease Rightofuse Asset0.02
Income taxes0.00
Losses/ -gains on Investments net3.83
Accounts Receivable-0.73
Increase (Decrease) in Accounts Payable-5.66
Increase (Decrease) in Accrued Liabilities19.96
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense1.62
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net-11.11
Payments for (Proceeds from) Other Operating Activities44.33
Discontinued operations0.00
Net Cash flow from Operating Activities-22.99
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-7.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-7.00
Financing Activities
Short-term debt Net9.64
Other borrowing transactions-0.89
Long-term debt - borrowings1.77
Long-term debt - repayments-1.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits0.00
Other financing activities net0.00
Other net32.23
Deferred Finance Costs Ownshare Lending Arrangement Issuance Costs Adjustment-
Proceeds From Convertible Promissory Notes-
Proceeds From Subordinated Convertible Promissory Note-
Proceed F Rom Deferred Offering Costs-
Increase Dicrease In Deferred Offering Costs-
Proceeds From Warrant One Exercises-
Net Proceeds From Registered Direct Offering-
Proceeds From Direct Offerings-
Net Proceeds From Underwritten Offerings-
Proceeds From Common Stock Option Exercises-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities42.74
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-22.99
Total Cash Flow12.76
4 historic quarters locked

Sign in to unlock the full Citius Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Citius Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-090185

Figures are derived from filed reports and may be restated. Historical data is subject to revision.